Rti Biologics, Inc. (RTIX) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RTI Biologics (RTIX) PT Lifted to $7 at Canaccord Genuity
February 13, 2015 7:58 AM ESTCanaccord Genuity reiterated a Buy rating on RTI Biologics (NASDAQ: RTIX) while boosting its price target to $7.00 (from $6.00) following solid Q4 results and 2015 guidance above the Street.
"Untitled Letter remains an overhang," the firm noted.
For an analyst ratings summary... More
